N-Acetylcysteine

What it is

N-acetylcysteine (NAC) is a modified form of the amino acid cysteine, best known as the standard antidote for acetaminophen (paracetamol) overdose and as a prescription mucolytic that thins mucus in chronic respiratory disease. It is also sold as a dietary supplement because it is a precursor for glutathione, the body's major intracellular antioxidant, and has anti-inflammatory properties. People take NAC supplements hoping to support respiratory health, general antioxidant status, or as an add-on alongside standard treatment for certain psychiatric conditions such as obsessive-compulsive disorder. Human evidence is strongest for long-term use in reducing chronic bronchitis and COPD exacerbations; evidence for general antioxidant benefits and psychiatric use is more preliminary and mixed. NAC has low oral bioavailability (roughly 6-10%) and is generally well tolerated, though it can meaningfully interact with nitrate medications such as nitroglycerin.

Evidence-based benefits

• Grade C· Preliminary evidence[1]

  NAC replenishes intracellular glutathione and has antioxidant and anti-inflammatory effects in laboratory and mechanistic research; this underlies its use across many conditions, though most of the supporting evidence for general antioxidant benefit in otherwise healthy people is mechanistic or preliminary rather than from dedicated, high-quality outcome trials.

  A 2021 clinical review describes NAC's core mechanism as replenishing glutathione stores and scavenging free radicals, and summarises supportive but mostly preliminary or small-trial evidence across a wide range of conditions (including polycystic ovary syndrome, infertility, and several psychiatric and neurological conditions). The author concludes NAC may be a useful adjunct as glutathione levels decline with age, but calls for more rigorous outcome trials in specific populations before broader recommendations can be made.

• Grade B· Limited evidence[1]

  Long-term oral NAC (used for at least 6 months) modestly reduces the frequency of COPD exacerbations, though it does not appear to improve lung function measures such as FEV1.

  A 2017 meta-analysis of 12 randomised controlled trials (2,691 patients) found both high-dose and low-dose NAC reduced COPD exacerbation prevalence versus placebo (relative risk 0.90 and 0.83 respectively), with the benefit driven by long-term use (>=6 months, RR 0.85) rather than short-term use. NAC did not significantly affect FEV1, forced vital capacity, or inspiratory capacity.

• Grade B· Limited evidence[1]

  As an add-on to SSRIs, NAC may modestly improve obsessive-compulsive disorder symptoms over several weeks of treatment, but the evidence is limited to a small number of trials and the effect is inconsistent across treatment durations.

  A 2024 systematic review and meta-analysis of 6 randomised controlled trials (195 patients) found NAC augmentation of SSRIs produced a significant improvement in total Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score after 5-8 weeks of treatment (p = 0.05), but no significant difference for treatment durations shorter than 5 weeks or longer than 12 weeks, and no significant separate effect on obsession or compulsion subscale scores. Adverse events did not differ significantly between NAC and placebo groups.

Risks & contraindications

• Grade B· Limited evidence[1]

  Oral NAC is generally well tolerated; when side effects occur they are usually mild gastrointestinal symptoms, and controlled trials have not found these to occur significantly more often than with placebo at typical doses.

  A systematic review of 11 randomised trials of oral NAC in chronic bronchitis (2,011 patients, treatment periods of roughly 12-24 weeks) found gastrointestinal adverse effects in 10.2% of NAC users versus 10.9% of placebo users, and withdrawal due to adverse effects in 6.5% versus 7.1%, indicating NAC did not increase the overall risk of adverse effects compared with placebo.

• Grade C· Preliminary evidence[1]

  NAC can potentiate the effects of nitroglycerin and likely other organic nitrates, increasing the risk of severe headache and symptomatic hypotension when the two are combined.

  A controlled crossover study in 11 healthy volunteers found that pretreatment with N-acetylcysteine (100 mg/kg) significantly potentiated nitroglycerin-induced headache (median headache score 3 vs 1 with placebo) and temporal artery dilation (139% vs 127% of baseline), an effect attributed to NAC's thiol group enhancing nitric oxide release from nitroglycerin.

Dosage & how to take it

• N-Acetylcysteine: 600–1800 mg/day, any time of day, with or without food. Some pharmacokinetic data suggest taking NAC on an empty stomach produces higher peak blood levels, but taking it with food can improve GI tolerability with little practical downside; either approach is reasonable. Doses used in respiratory trials (600-1800 mg/day) were typically split into 2-3 doses.

Interactions

No interactions in our database yet. We check against a limited set of medications. Absence of a warning is not evidence of safety.

Our medication coverage is not exhaustive. Absence of a warning here is not evidence of safety. Always confirm with your pharmacist.

Check this against your whole stack

Where to buy

Checking current prices…